News for AGRX Stock

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L. Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L. Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update Agile Therapeutics Announces Delisting from Nasdaq Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024 Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024 Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024 Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023 Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023 This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden’s Latest Executive Order Expanding Contraceptive Coverage H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023 Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About? The Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of Care Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla® Agile Therapeutics Announces Closing of $7.5 Million Public Offering Agile Therapeutics Announces Pricing of $7.5 Million Public Offering Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023 Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023 Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement Agile Therapeutics Announces 1-For-50 Reverse Stock Split Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023 Corium Pharma Solutions Names Suzanne Hinchliffe as Chief People Officer Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer Corium Pharma Solutions Names Two Industry Veterans to its Executive Team Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022 Agile Therapeutics Announces Reorganization of Leadership Team Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference Agile Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022 Agile Therapeutics Updates Second Quarter 2022 Guidance Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference Agile Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022 Agile Therapeutics Announces 1-For-40 Reverse Stock Split Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla® Agile Therapeutics Receives $4.7M After Selling Net Operating Loss Tax Benefits Through New Jersey Economic Development Program Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG) Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z Agile Therapeutics Reports Fourth Quarter & Full Year 2021 Financial Results and Provides Corporate Update Agile Therapeutics Announces Closing of $4.85 Million Registered Direct Offering Agile Therapeutics Announces $4.85 Million Registered Direct Offering Agile Therapeutics to Participate in Upcoming March Investor Events Agile Therapeutics to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Wednesday, March 30, 2022 Agile Therapeutics Acknowledges New Government Guidance Reinforcing Requirement to Cover Contraceptives that a Woman and Her Heathcare Provider Determine are Medically Appropriate at No Cost Agile Therapeutics and Afaxys Partner to Expand Access to Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System Agile Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference Agile Therapeutics to Present at the Biotech Showcase and H.C. Wainwright BioConnect Virtual Conferences Agile Therapeutics Reports Third Quarter 2021 Financial Results Agile Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on Tuesday, November 2, 2021 Agile Therapeutics Applauds Congressional Chairs’ Letter to Biden Administration Requesting Enforcement of Contraceptive Access Under Affordable Care Act Agile Therapeutics Appoints Josephine Torrente to its Board of Directors Agile Therapeutics Announces Pricing of $22,666,650 Underwritten Public Offering of Common Stock and Warrants Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Warrants Agile Therapeutics Announces Addition of Twirla® to a Preferred Drug Position on Medi-Cal Formulary Agile Therapeutics Partners with Carli Lloyd, U.S. Women’s Soccer Star and Four-Time Olympian, to Bring Awareness to Women’s Health Topics Agile Therapeutics to Participate in Upcoming Investor Conferences Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women’s Access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system Agile Therapeutics Reports Second Quarter 2021 Financial Results Agile Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on Monday, July 26, 2021 Agile Therapeutics to Participate in the William Blair 41st Annual Growth Stock Conference Agile Therapeutics to Participate in Virtual Fireside Chat as Part of the 2021 RBC Capital Markets Global Healthcare Conference Agile Therapeutics Reports First Quarter 2021 Financial Results Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting CORRECTING AND REPLACING -- Agile Therapeutics Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020 Agile Therapeutics to Present at Upcoming March Investor Conferences Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Monday, March 1, 2021 Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System, a New Non-Daily, Non-Invasive Contraceptive Patch Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System in Contraception Agile Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference Agile Therapeutics Reports Third Quarter 2020 Financial Results Agile Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Provide Corporate and Twirla® Commercial Updates on Thursday, November 12, 2020 Agile Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference Agile Therapeutics Announces Virtual Investor/Analyst Day on Monday, September 21, 2020 Agile Therapeutics Launches I’m So Done Campaign to Inspire Women to Take an Active Role in Choosing their Birth Control Agile Therapeutics to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference Agile Therapeutics Reports Second Quarter 2020 Financial Results Agile Therapeutics to Join Russell 3000® and 2000® Indexes Agile Therapeutics to Host Second Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, August 11, 2020 Agile Therapeutics Reports First Quarter 2020 Financial Results